EIKN · XBRL financial data
Eikon Therapeutics financial statements, every quarter
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters
| In millions of dollars | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|
| Research and development | 70 | 75 |
| General and administrative | 17 | 18 |
| Total operating expenses | 87 | 93 |
| Other operating income (expense) | (0) | (0) |
| Operating income (loss) | (87) | (93) |
| Net income (loss) | (83) | (88) |
| Earnings per share, basic USD per share | (2.46) | (1.63) |
| Earnings per share, diluted USD per share | (2.46) | (1.63) |
| Weighted average shares, basic millions of shares | 34 | 54 |
| Weighted average shares, diluted millions of shares | 34 | 54 |
Balance sheet
CSVFiscal quarters
| In millions of dollars | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|
| Cash and cash equivalents | 161 | 143 |
| Marketable securities | 351 | 389 |
| Marketable securities, non-current | 84 | — |
| Prepaid and other current assets | 17 | 15 |
| Total current assets | 530 | 547 |
| Property and equipment, net | 138 | 133 |
| Right-of-use asset | 91 | 91 |
| Total assets | 851 | 780 |
| Accounts payable | 6 | 7 |
| Total current liabilities | 45 | 55 |
| Lease liability, non-current | 245 | 243 |
| Total liabilities | 300 | 313 |
| Accumulated deficit | (1,003) | (1,092) |
| Total stockholders' equity | 551 | 467 |
| Total liabilities and equity | 851 | 780 |
| Common shares outstanding (cover page) millions of shares | 54 | 54 |
Cash flows
CSVFiscal quarters
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Eikon Therapeutics | 143 | not reported | (65)* | 54.2M | 8.2 quarters | 10-QJun 30, 2026 |
| Acumen Pharmaceuticals | 53 | not reported | (27)* | 72.3M | 3.4 quarters | 10-QSep 30, 2026 |
| Alpha Cognition | 41 | 6.1 | (6.9)* | 21.8M | 6.0 quarters | 10-QJun 30, 2026 |
| Adaptimmune Therapeutics | 26 | 14 | (35)* | 1.6B | 0.7 quarters | 10-QJun 30, 2025 |
| Adma Biologics | 125 | 141 | 17* | 221.9M | — | 10-QSep 30, 2026 |
| Adaptive Biotechnologies | 76 | 84 | 9.6* | 161.9M | — | 10-QSep 30, 2026 |
| Adverum Biotechnologies | 26 | 0 | (28)* | 22.1M | 0.9 quarters | 10-QSep 30, 2025 |
| Agenus | 67 | 31 | (20)* | 45.2M | 3.0 quarters | 10-QSep 30, 2026 |
| Agentix | 0 | not reported | (0) | 40.1M | 0.0 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.